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Prolonged and profound neutropenia, deﬁned as an
absolute neutrophil count of <500⁄lL for more than ten
consecutive days, is a common severe complication dur-
ing remission induction chemotherapy of patients with
acute myeloid leukaemia (AML) or myelodysplastic syn-
drome (MDS) (1). Invasive fungal infection (IFI) is a
major cause of mortality in patients with neutropenia
caused by a haematologic malignancy, its therapy or
both. Fatality rates range from 60% to 90% and even
non-fatal IFIs complicate or delay further chemotherapy,
thereby impairing the treatment for the haematologic
underlying disease (2, 3). The incidence of IFI has
increased within the recent years, because of a rise in the
number of immunocompromised patients (4–6). Reasons
are supposed to be changes in the treatment for haema-
tologic malignancies: formerly by more intensive cyto-
toxic treatment, nowadays by increasing number of
elderly patients treated curatively and of transplantations
with stem cells of unrelated or mismatch donors (5, 7).
Early diagnosis of IFI is difﬁcult as symptoms (e.g. fever
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become rapidly fatal. Therefore, antifungal prophylaxis
is a commonly used management strategy in patient pop-
ulations with neutropenia (5, 8). Most IFIs in immuno-
compromised patients are caused by Candida species, but
during the last years, the epidemiology of IFI changed.
The adoption of antifungal prophylaxis has lead to a
decrease in invasive candidiasis, in parallel with the
occurrence of resistant Candida species and with an
increase in infections by Aspergillus species and other
ﬁlamentous fungi (9, 10).
Posaconazole, a novel broad-spectrum azole, has
received approval by the European Medicines Agency
(EMA) and by the US Food and Drug Administration
(FDA) in 2006 (11). The efﬁcacy of posaconazole as pro-
phylaxis in high-risk patients has been shown to be supe-
rior to that of either ﬂuconazole or itraconazole (12).
Therefore, the European Conference on Infections in
Leukemia recommends posaconazole for prophylaxis in
allogeneic haematopoietic stem cell transplant recipients
and patients receiving induction chemotherapy for acute
leukaemia (5, 13).
In addition to increased morbidity and mortality of
the affected patients, treatment for fungal infections is
associated with signiﬁcant costs for the healthcare sys-
tem. The hospitalisation costs of patients with aspergillo-
sis in 2009 were estimated to be, dependent on the
underlying disease, between US $48 110 and US $80 468
higher than those of comparable patients without the
infection (14, 15).
Budget constraints to hospitals are increasing over the
time, and introduction of new substances or new indica-
tions resulting in extended use gives rise to objections
about resource allocation and possible cost increase. This
study addresses antifungal prophylaxis and treatment
patterns as well as resource use related to the manage-
ment of patients with AML after chemotherapy from
hospital provider (HP) perspective in Germany from
2004 to 2006 with a special focus on prophylaxis and
treatment for IFI. To provide real-life data for posaco-
nazole, the analysis was carried out also for a subgroup
of patients who had received posaconazole prophylaxis
(PP) in 2006.
Patients and methods
The study was conducted as a retrospective, single centre
chart review in hospitalised AML patients after myelo-
suppressive chemotherapy from January 2004 to Decem-
ber 2006 in the University Hospital⁄Frankfurt Main,
Germany. During the years 2005 and 2006, both chemo-
therapy regimens and antifungal management (except the
posaconazole prophylaxis that was introduced in January
2006) had been nearly identical.
Data collection
Information was obtained from medical records. All
information was recorded onto structured data abstrac-
tion forms. Proven or probable IFI was diagnosed
according to EORTC⁄MSG deﬁnitions (16). Resource
utilisation was collected covering the complete hospital
stay in patients hospitalised because of chemotherapy,
neutropenia and⁄or infections. The admission date was
considered as index date, and all data were collected
from this point onward until the date of discharge. The
following resource utilisation data were considered: inpa-
tient stay (normal ward or ICU), mechanical ventilation,
parenteral feeding, diagnostics, systemic antifungal medi-
cation, cost-intensive concomitant medication. Adverse
events were collected and reported to Essex Pharma.
Resource use and cost analysis
Direct medical costs per episode associated with above-
mentioned resource utilisation were calculated from the
HP perspective.
To evaluate costs, the quantity of each resource con-
sumed was multiplied by the respective unit cost for each
resource (e.g. price per tablet or injection, cost for hospital
stay). Different cost data sources were used for calcula-
tion. Medications were multiplied by the prices according
to the German pharmaceutical index ‘Rote Liste’ reduced
by margins for hospital pharmacies (17). Unit cost for
diagnostics was obtained from DKG-NT (18). Unit costs
for hospital stay (without medication and procedures)
were taken from a hospital internal database. Unit cost
for transfusions was derived from manufacturers directly
or from a pharmacy department of a university hospital.
The analyses were conducted for complete hospitalisa-
tion episodes, which mainly included the chemotherapy
plus following neutropenic period plus infection complica-
tion. Until 2004, the patients were mainly hospitalised
from start of chemotherapy until regeneration of neutroph-
ils, but during 2004, the admission policy gradually began
to change: a percentage of patients (about 10% each year)
were discharged after the end of chemotherapy if clinically
justiﬁed and re-admitted at the onset of neutropenia (neu-
trophil count <500⁄lL). In these cases, consisting of two
hospital stays for the same chemotherapy episode resource
consumption and related cost of the hospitalisations were
added to achieve results for the episode as a whole.
Occurrence of IFI, antifungal management and total
costs per episode were stratiﬁed by year of treatment
(2004, 2005 and 2006). The costs for antifungals included
also the antifungal prophylaxis. Total costs were also
stratiﬁed by chemotherapy regimen for the subgroup of
patients receiving PP compared with patients without PP.
Based on the number of available episodes for analysis in
the PP group, the following two chemotherapy regimens
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poside (regimen ICE; dosages for younger patients) ±
valproic acid ± all-trans-retinoid acid and idarubicin⁄cyt-
arabine⁄etoposide (regimen IDAV; dosages for elderly
patients) (induction 1 or 2 each), which are described later
in detail. Posaconazole prophylaxis was applied only in
2006. Patients without PP were pooled from the years
2005 and 2006, because treatment patterns in both years
were quite similar (e.g. antifungal management).
Cytostatic and supportive therapy regimens in
patients with AML
During the study period, the patients had been treated
with following chemotherapy ﬁrst-line regimens:
Patients £60 yr.
2004: SHG-Hannover-AML-1⁄99 (19): two induction
cycles idarubicin⁄cytarabine⁄etoposide, two consolidation
cycles with daunorubicin⁄cytarabine (1· intermediate dose,
1· high-dose: 2 · 3g⁄qm day 1–6). For non-responders
after ﬁrst induction: one cycle ﬂudarabine⁄idarubicin⁄cyt-
arabine⁄granulocyte colony-stimulating factor (G-CSF)
and one cycle high-dose cytarabine.
2005⁄2006: AMLSG 07⁄04 (20): similar induction
cycles, less intensive consolidation with three cycles
cytarabine 2 · 3g⁄qm day 1, 3, 5; all cycles ± all-trans-
retinoid acid and ± valproic acid. At the end of 2006,
this protocol was changed and valproic acid was stopped.
Patients ‡61 yr.
2004 until approximately October 2006: SHG-Frankfurt-
AML-Elderly 1⁄99 (21): two cycles idarubicin⁄cytara-
bine⁄etoposide with G-CSF priming. First consolidation
with ﬂudarabine⁄reduced dosed idarubicin⁄intermediate
dosed cytarabine, second consolidation with autologous
stem cell transplantation if possible.
Since October 2006: AML-Sorafenib-phase II-Trial for
Elderly (not published so far; ClinicalTrials.gov Identi-
ﬁer: NCT00373373:): one induction with daunorubi-
cin⁄cytarabine, two consolidation cycles with cytarabine
2g⁄qm day 1 + 3 + 5, all cycles ± sorafenib and
sorafenib maintenance therapy for 1 yr.
The intensity of cytostatic relapse regimen did not
markedly differ during 2004-2006. None of the study
protocols excluded an antifungal prophylaxis with triaz-
oles. Moreover, sorafenib has not shown any interactions
with ketoconazole (22).
Empirical and prophylactic antifungal therapy in
persistent febrile neutropenia
Empirical antifungal therapy: In 2004, most patients
received oral voriconazole or liposomal amphotericin B
(L-AmB) 1–3 mg⁄kg. Owing to increasing fatal invasive
mycoses in elderly patients, the empirical therapy was
changed to liposomal AmB 3 mg⁄kg or caspofungin in
2005. This regime was continued during 2005 and 2006.
Prophylactic antifungal therapy: In 2004⁄2005, the
patients did not receive any systemic antimycotic prophy-
laxis except secondary prophylaxis (mainly with vorico-
nazole) in patients with prior invasive mycoses and
further intensive chemotherapy. After presentation of
study results by Cornely et al. (23) at the Annual Con-
gress of the American Society of Hematology in 2005
(published in 2007), the prophylaxis with posaconazole
in newly diagnosed AML and AML relapse induction
cycles was established in January 2006.
Statistics
Data were analysed by sas system (version 9.1) (SAS
Institute Inc., Cary, NC, USA). For descriptive purposes,
mean, median, standard deviation (SD), minimum and
maximum were calculated for continuous variables and
absolute and relative frequencies for categorical parame-
ters. T-test and Wilcoxon two-sample test were used for
the explorative comparison of continuous variables pre-
sented in two groups. Differences in distributions of con-
tinuous variables in more than two groups (e.g.
evaluated parameters in three study observational years
– 2004, 2005, 2006) were tested by using anova. The cat-
egorical variables such as percentage of patients with dif-
ferent disease status or gender distribution were tested
exploratively with chi-square test. With respect to the
exploratory character of analysis, no adjustment for mul-
tiple testing was undertaken.
Results
In total, data for 478 episodes in 214 patients hospita-
lised during 2004–2006 were documented within 531 hos-
pital stays. A total of 471 episodes in 212 patients were
eligible for analysis (Fig. 1). Seven episodes were
excluded because of the following reasons: four episodes
(eight hospital stays) with PP during one hospital stay
only; three episodes with PP and later treatment with
posaconazole during the same hospital stay. In 2006, 55
patients received PP and 105 patients had not received
PP because of other chemotherapy than induction, ini-
tially increased liver parameters, possibly problematical
comedications. Demographic and clinical characteristics
are summarised in Table 1. We found no signiﬁcant dif-
ferences in gender and de novo, secondary or relapsed
AML over the 3 yr. Mean age differs signiﬁcantly caused
by the difference between 2005 and 2006, but did not
result in a signiﬁcant difference between the percentage
of patients below and above 60 yr. The median duration
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from 2004 to 2006. Signiﬁcant differences have been
remarked regarding the disease status with a lower
percentage of patients with controlled AML in 2006.
Differences over years observed in both patient groups
treated with IDAV and ICE with respect to disease
status and duration of neutropenia were not statistically
signiﬁcant. In patients receiving IDAV, median duration
of neutropenia was signiﬁcant lower than in patients
receiving ICE (P = 0.0243).
Overall, probable or proven IFI was observed in 17 of
471 episodes (3.6%) (Table 2). Stratiﬁed by year, the
occurrence of IFI decreased from 5.9% in 2004 to 1.9%
in 2006. In patients with PP, no probable or proven IFI
was documented.
More IFIs were observed in patients >60 yr (11 of
17), but the result was not statistically signiﬁcant because
of small sample size.
The mean number of hospitalisation days decreased
from 28,7 ± 17,9⁄29.3 ± 15.8 d in 2004⁄2005 to
22,4 ± 11.8 d in 2006. The differences between
2004⁄2005 and 2006 were statistically signiﬁcant
(P < 0.05).
The treatment patterns stratiﬁed by year in all eligible
episodes (n = 471) are displayed in Table 3. With the
exception of the use of imaging techniques (decline from
69.6% to 57.5% of patients) and growth factors (decline
from 54.5% to 45.0% of patients), the treatment patterns
were quite similar in 2004, 2005 and 2006.
Figure 1 Disposition of hospitalisation episodes (PP, posaconazole
prophylaxis).
Table 1 Demographic and clinical characteristics
2004 2005 2006 P-value
Number of patients 83 77 80
Mean age in years (SD) 59 (13) 57 (16) 63 (14) 0.0356
Percentage of patients >60 yr (in %) 59 51 68 >0.05
Sex distribution in % (male⁄female) 60⁄40 55⁄45 59⁄41 >0.05
Underlying disease n (%)
1
AML de novo 41 (49) 37 (48) 45 (56) >0.05
AML secondary 34 (41) 36 (47) 27 (34)
AML relapse 8 (10) 4 (5) 8 (10)
Number of episodes 135 176 160
Disease status n (%)
3
AML uncontrolled 37 (28) 31 (18) 49 (31) 0.0160
AML controlled 84 (62) 132 (75) 87 (54)
Not available 14 (10) 13 (7) 24 (15)
Median duration of neutropenia in days
§ 16 (0 – 79) 16 (0–75) 17 (0–71) >0.05
Number of episodes – IDAV 30 31 21
Disease status n (%)
3
AML uncontrolled 9 (30) 6 (19) 3 (14) >0.05
AML controlled 18 (60) 25 (81) 17 (81)
Not available 3 (10) – 1 (5)
Median duration of neutropenia in days
§ 19.5 (4–56) 16.0 (3–70) 15.0 (0–40) >0.05
Number of episodes – ICE 7 43 24
Disease status n (%)
3
AML uncontrolled 0 () 4 (9) 4 (17) >0.05
AML controlled 7 (100) 39 (91) 20 (83)
Not available – – –
Median duration of neutropenia in days
§ 19 (12–23) 21 (0–38) 22.5 (10–71) >0.05
AML, acute myeloid leukaemia.
P > 0.05: not signiﬁcant.
1At the ﬁrst documented hospital stay.
§Including patients without neutropenia.
3At discharge.
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signiﬁcantly increased from 30.4% to 46.9%, whereas
the use of multiple antifungal drugs signiﬁcantly
decreased from 24.4% to 13.1% (Table 4). Single anti-
fungal drug use was dominated by azoles (14.1%⁄12.5%)
and increased from 23.7% in 2004 to 43.4% in 2006.
Treatment with multiple antifungal drugs was dominated
by the use of two drugs (two azoles, azole and L-AmB,
azole and caspofungin). In 2004⁄2005 in 15.6%⁄15.3%
of episodes, two antifungal drugs were applied, and in
2006 11.3%. The use of three or more antifungal drugs
within one episode was necessary in 8.9% of episodes in
2004, 5.1% in 2005 and 1.9% in 2006. In patients with
PP, in 76.4% of episodes, no further antifungal drug was
necessary. In episodes with additional antifungal drug
therapy (23.6%), especially an azole (10.9%) and caspo-
fungin (7.3%) were administered.
With the exception of posaconazole, the use of antimy-
cotics declined from 2004 to 2006. The use of L-AmB
declined from 21.4% to 3.8%, caspofungin from 19.3%
in 2005 to 8.1%, ﬂuconazole from 25.2% to 11.9% and
voriconazole from 31.9% to 15.0%. This was accompa-
nied with a reduction in the mean application period of
L-AmB, caspofungin and voriconazole, but not observed
for ﬂuconazole (Table 5).
Overall, total costs amounted to €17 352 ± 15 971 per
episode. The main cost drivers were hospital stay (42.1%),
blood products (20.0%) and antimycotics (16.4%) fol-
lowed by growth factors (10.1%) and antibiotics (8.1%).
Total costs per episode declined from €19 051 ±
19 024⁄€19 523 ± 17 599 in 2004⁄2005 to €13 531 ±
9260 in 2006. The difference between 2004⁄2005 and 2006
was statistically signiﬁcant (P < 0.05). The main reduc-
tion was observed in the use of antimycotics (from
€3051 ± 6271⁄€3962 ± 7806 in 2004⁄2005 to €1463 ±
2688 in 2006) and in hospital stay (from €7709 ±
5429⁄€8106 ± 5425 in 2004⁄2005 to €6065 ± 3254 in
2006) (Fig. 2). Both differences were statistically signiﬁ-
cant (P < 0.05).
The stratiﬁcation of costs was also conducted for
patients with and without PP (Fig. 3). In patients after
IDAV chemotherapy, mean total costs were signiﬁcantly
lower in patients receiving PP than in patients without
PP (€17 880 ± 5059 vs. €29 359 ± 25 777; P = 0.0166).
In patients after ICE chemotherapy, mean total costs
were comparable (with PP: €20 474 ± 7510; without PP:
€20 961 ± 13 433; P = 0.8533). In patients after IDAV
chemotherapy, costs for antimycotics were signiﬁcantly
lower in patients receiving PP (€1494 vs. €5016;
P = 0.0202). In patients receiving ICE chemotherapy,
costs for antimycotics were quite comparable (€3562 vs.
€4144; P = 0.6556).
Discussion
Presented analyses provide ﬁrst real-life data on the man-
agement of patients with AML after chemotherapy in a
German University hospital over a time period of 3 yr
with a special focus on antifungal treatment. These anal-
yses are important to reﬂect the impact of new strategies
in patient management on outcomes and cost.
Our data indicate a decline in the length of hospital
stay from 2004⁄2005 to 2006 together with a consider-
able decline in total costs per patient episode. The length
of hospital stay depends markedly on the intensity of
chemotherapy regimens and duration of neutropenia,
which is one of the most important risk factors for severe
infections. Despite the attenuation of chemotherapy
intensity, for example in consolidation therapy, especially
by cytarabine dose reduction (see patients and methods),
the duration of neutropenia did not differ from 2004 to
2006. A tendency to higher percentage of patients with
uncontrolled leukaemia found in 2006 was possibly
Table 2 Occurrence of invasive fungal infections (IFI) (n = 471 hospi-
talisation episodes)
2004
% of episodes (n)
(n = 135)
2005
% of episodes (n)
(n = 176)
2006
% of episodes (n)
(n = 160)
IFI overall 5.9 (8) 3.4 (6) 1.9 (3)
Probable 1.5 (2) 1.7 (3) 1.3 (2)
Proven 4.4 (6) 1.7 (3) 0.6 (1)
IFI overall, by age group
£60 yr 3.2 (2) 2.8 (3) 1.6 (1)
>60 yr 8.3 (6) 4.4 (3) 2.0 (2)
The distribution of IFI by age group (combining 2004–2006) compared
with the group without IFIs is not statistically signiﬁcant (P = 0.2408;
chi-square).
Table 3 Treatment patterns (n = 471 hospitalisation episodes)
Percentage of episodes in %
2004
(n = 135)
2005
(n = 176)
2006
(n = 160)
Hospital stay
Haematology ward 100.0 98.9 99.4
ICU 4.4 6.8 7.5
Mechanical ventilation 1.5 3.4 3.8
Parenteral feeding 3.0 4.0 3.1
Diagnostic procedures
Imaging techniques 69.6 64.2 57.5
Microbiological tests 80.7 84.1 85.6
Prophylaxis and treatment
Antibiotics 86.7 85.8 83.8
Antimycotics 54.8 59.7 60.0
Virustatics – 1.7 –
Growth factors 54.8 45.5 45.0
Blood products 94.8 91.5 94.4
ICU, intensive care unit.
Management of patients with AML after chemotherapy Bo ¨hme et al.
72 ª 2011 John Wiley & Sons A/Srelated to higher number of elderly patients. So, two
main risk factors for prolonged hospital stay and occur-
rence of IFI have not decreased over the years. This is a
crucial point for the assessment of the impact of posaco-
nazole on resource use and associated cost. In contrast,
the lower rate of IFI in 2006 may be a cause for shorter
hospital stay. Besides the hospital stay, the trend towards
lower cost was especially high in antimycotics and blood
products.
During the last years, general efforts have been made to
develop evidence-based strategies and recommendations
for antifungal prophylaxis and treatment in patients with
haematologic malignancies considering the epidemiologi-
cal change to invasive aspergillosis (5, 8, 10, 24, 25). The
higher costs for antifungal therapy in 2005 are caused by
the change of empirical antifungal treatment preferring
cost-intensive antimycotics like L-AmB and caspofungin.
In 2006, both substances were less frequently used as well
as applicated over a shorter time period than in 2005.
These change resulted in a decline of antimycotic cost.
The reduced use of L-AmB and caspofungin in 2006 may
be interpreted as a consequence of an effective antifungal
prophylaxis with posaconazole. Other causes, however,
may have contributed to reduction in fungal infections
and use of antifungal medication, e.g. AML remission
rates or duration of neutropenia. But the comparison of
neutropenia periods did not show statistically signiﬁcant
differences during the years, and the percentage of epi-
sodes with controlled leukaemia was signiﬁcantly lower in
2006 compared with 2005. The inpatient exposure to
aspergillus spores (air, bathroom⁄showers and other) may
have differed also, but this factor is in general difﬁcult to
address. The increased use of a single drug regimen in
2006 may also be assessed as an indirect parameter for
effective antifungal prophylaxis with lower rate of empiri-
cal and targeted antifungal treatment.
No probable or proven IFI was documented in the
total PP group, and only in 13 of 55 episodes, additional
Table 4 Distribution of antimycotics, stratiﬁed by year (n = 471 hospitalisation episodes)
2004
% of episodes (n)
(n = 135)
2005
% of episodes (n)
(n = 176)
2006
% of episodes (n)
(n = 160)
P-value
No antimycotics 45.2 (61) 40.3 (71) 40.0 (64) >0.05
Single drug use 30.4 (41) 39.2 (69) 46.9 (75) 0.0153
Azole 23.7 (32) 29.6 (52) 43.4 (70)
L-AmB 5.2 (7) 2.8 (5) 0 (0)
Caspofungin 1.5 (2) 6.8 (12) 3.1 (5)
Multiple drugs use 24.4 (33) 20.4 (36) 13.1 (21) 0.0408
Two azoles 6.7 (9) 2.3 (4) 5.0 (8)
Azole⁄L-AmB 5.9 (8) 5.7 (10) 1.3 (2)
Azole⁄caspofungin 1.5 (2) 5.7 (10) 4.4 (7)
L-AmB⁄azole⁄caspofungin 4.5 (6) 4.0 (7) 0 (0)
Two azoles⁄L-AmB 3.0 (4) 0 (0) 1.9 (3)
Two azoles⁄caspofungin 0 (0) 1.1 (2) 0 (0)
L-AmB⁄caspofungin 1.5 (2) 1.7 (3) 0.6 (1)
L-AmB⁄two azoles⁄caspofungin 1.5 (2) 0 (0) 0 (0)
L-AmB, liposomal amphotericin B.
When two, three or four antimycotics are listed, they were given sequentially, overlapping or as combination therapy in different formulations.
Table 5 Duration of application of antimycotics in days, stratiﬁed by year (n = 471 hospitalisation episodes)
2004
(n = 135)
2005
(n = 176)
2006
(n = 160)
% of patients Mean⁄SD in days % of patients Mean⁄SD in days % of patients Mean⁄SD in days
L-AmB (n =2 9⁄25⁄6) 21.5 12.6⁄12.3 14.2 14.1⁄12.0 3.8 7.2⁄3.4
Caspofungin (n =1 4⁄34⁄13) 10.4 14.8⁄15.7 19.3 19.4⁄15.4 8.1 12.2⁄6.6
Fluconazole (n =3 4⁄45⁄19) 25.2 8.2⁄6.0 25.6 10.0⁄6.2 11.9 10.2⁄6.8
Itraconazole (n =1⁄1⁄0) 0.7 –
1 0.6 –
1 0.0 –
Posaconazole (n =0⁄0⁄58) 0.0 – 0.0 – 36.3 16.3⁄7.2
Voriconazole (n =4 3⁄42⁄24) 31.9 13.2⁄11.3 23.9 14.2⁄10.6 15.0 9.1⁄10.1
L-AmB, liposomal amphotericin B.
1Value for one patient not shown.
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discussed with respect to aforementioned changes in
cytostatic treatment, which may have contributed to a
lower incidence of invasive mycoses in 2006. To circum-
vent the impact of that factor, we compared a small sub-
group of 55 patients in induction therapy of AML
(IDAV or ICE) receiving PP with patients undergoing
the same chemotherapy regimens, but without PP. The
empirical antifungal regimen was the same for both
groups. The introduction of PP did not lead to an
increase of costs. In contrast, for patients after IDAV
chemotherapy, total costs per episode were considerably
lower in patients with PP than in patients without PP.
For the younger patients after ICE induction, however,
total costs were quite similar in the PP group compared
with the group without PP. That is astonishing, because
the duration of neutropenia in ICE episodes was mark-
edly longer, so a higher rate of IFI would have to be
expected. In elderly patients, however, a generally higher
risk of incidence and morbidity of IFI have been
described (26, 27), which may be correlated with more
extensive comorbidities. Also, the higher number of
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(idarubicin⁄cytarabine⁄etoposide; dosage for younger patients) ± valproic acid ± all-trans-retinoid acid or IDAV regimen (idarubicin⁄cytarabine⁄eto-
poside; dosage for elderly patients); others: parenteral feeding, ventilation, diagnostics, virustatics and other drugs; PP, posaconazole prophylaxis.
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lower remission rate may play a role (28). Also in our
complete patient population, a tendency to higher num-
ber of IFI in elderly patients could be found, but the dif-
ference was not statistically signiﬁcant. In summary, the
introduction of PP did not result in higher costs. In
elderly patient with AML induction therapy with IDAV,
the PP was cost-saving.
In general, a comparison between healthcare costs gen-
erated in different countries has to be assessed carefully
because of the differences of the health systems and
charges for utilised resources.
Comparable data on total medical costs are available
for the treatment of invasive aspergillosis in patients with
haematologic malignancies. In a study conducted in the
Netherlands on 269 patients, 12% had possible and 18%
had probable or proven invasive aspergillosis. Mean
medical costs per patient corrected for duration of neu-
tropenia amounted to €21 130, €29 490 and €36 410
(costs for 2007) for patients without, with possible and
with probable or proven invasive aspergillosis, respec-
tively (29). Cost data from the USA arise to total hospi-
tal charges of US $191 974 ± 163 535 and US
$45 064 ± 69 220 (costs for 2003) for patients with
haematologic malignancies with or without aspergillosis,
respectively (30). Taking the relatively low rate of IFI
(4%) in our study into account, presented cost data are
considerably lower than the costs evaluated for 2003 in
the USA and somewhat lower than average cost without
IFI in the Netherlands.
Our presented cost data of nearly €20 000 per episode
in 2004⁄2005 correspond to data reported in a single cen-
tre bottom-up study from Germany. The direct costs in
patients with AML for hospitalisation because of persis-
tent fever and neutropenia amounted to €19 039 (95%
conﬁdence interval: €17 050–€21 029; costs for 2002)
(31).
Many attempts have been undergone to save costs in
the antimycotic treatment. In a multicentre randomised
trial on high-risk, febrile, neutropenic patients with
haematologic malignancies in France, the researchers
found decreased costs of antifungal therapy by 35% for
pre-emptive compared with empirical treatment (32).
Pre-emptive treatment was deﬁned as treatment of
patients who had not only persistent or recurrent fever,
but additional clinical, imaging or laboratory signs of
fungal disease. First-line antifungal treatment was
amphotericin B deoxycholate or L-AmB. In the pre-emp-
tive group, 9.1% of patients had probable or proven IFI,
whereas in the empirical group, only 2.7% (32). Mean
costs for antifungal drugs amounted to €2252 SD €4050
in the empirical treatment group and to €1475 SD €3329
in the pre-emptive treatment group (costs for 2005). If L-
AmB was used instead of amphotericin B deoxycholate,
estimated costs were €4261 ± 4760 and €2509 ± 4099 in
both groups, respectively. The declining average costs for
antimycotics from €3051⁄€3962 in 2004⁄2005 to €1463 in
2006 are therefore in line with the data from the litera-
ture and reﬂect a general change in treatment strategies.
It should be mentioned that more proven invasive IFIs
were observed in the pre-emptive treatment group, and
the authors concluded that ‘empirical treatment may pro-
vide better survival rates for patients receiving induction
chemotherapy’.
According to a retrospective chart analysis in United
States, the introduction of posaconazole did not lead to
a change in the use or costs for antimycotics, antibiotics
or total medications in the same patient setting (33). In
contrast, results of decision analytic modelling on the
cost-effectiveness of posaconazole in comparison with
standard prophylaxis (itraconazole or ﬂuconazole) sug-
gest cost – saving potential of posaconazole in different
European countries and United States (11, 34, 35). In
about 53–87% of model population, prophylaxis with
posaconazole leads to lower cost per patient with respect
to costs of prophylaxis and IFI treatment than in the
comparator group.
Further studies would be necessary to demonstrate the
effectiveness of posaconazole prophylaxis in comparison
with other prophylactic treatment regimens under real-life
conditions in equivalent patient groups. But study results
always depend on the hospital-speciﬁc risk factors, espe-
cially risk for aspergillosis (construction activities, hygie-
nic conditions on the wards, air ﬁltration and more) and
especially the empirical treatment regimens. In multicen-
tre studies, these effects may be levelled and the results
may have no consequences for single hospitals. Cost-
effectiveness of PP may be given in hospitals with higher
rate of aspergillosis, internal recommendations preferring
rigorous empirical therapy without waiting for given cri-
teria for pre-emptive start and high use of expensive anti-
fungal therapies. According to our experiences, a higher
IFI risk in elderly patients with AML may be considered
even if they are treated with lower intensive chemother-
apy regimes. Meanwhile, it is important to consider also
the gain in quality of life, which is given not only by
reduced mortality but also by reduced morbidity.
All these aspects and the fact that posaconazole is rec-
ommended for antifungal prophylaxis in AML induction
therapy with the highest level strength of recommenda-
tion and quality of evidence in national as well as inter-
national guidelines may complicate the decision for or
against posaconazole prophylaxis (8). Hospital- and
patient-speciﬁc risk factors should be decisive.
Some limitations of our study have to be mentioned.
The study was conducted retrospectively in a single
centre. The impact of PP on the occurrence of IFI was
shown descriptively, but could not be assessed with
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patient numbers of the analysed subgroups with induc-
tion treatment ICE and IDAV are too small to provide
concluding results, but may serve as a starting point for
further research.
In conclusion, our real-life data from one single cen-
tre in Germany demonstrate a change in antifungal
management of AML⁄MDS patients between 2004⁄2005
and 2006, accompanied by a decline in total costs.
Reduced use of multiple antifungal drugs and decreas-
ing antifungal therapies after introduction of posaconaz-
ole prophylaxis in 2006 could be demonstrated.
Additional research is necessary to further improve anti-
fungal strategies and to update cost development con-
tinuously.
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